Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.

[1]  S. Jaffer,et al.  Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer , 2022, Cancer.

[2]  A. Prat,et al.  A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes , 2022, NPJ breast cancer.

[3]  P. Fasching,et al.  Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  E. Rutgers,et al.  Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Ellis,et al.  Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group , 2020, Journal of the National Cancer Institute.

[6]  K. Czene,et al.  Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer , 2020, JNCI cancer spectrum.

[7]  M. Gnant,et al.  Breast cancer , 2019, Nature Reviews Disease Primers.

[8]  L. Saal,et al.  Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer , 2019, Breast Cancer Research and Treatment.

[9]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Mitch Dowsett,et al.  Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer , 2018, Nature Reviews Clinical Oncology.

[11]  A. Arance,et al.  Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.

[12]  E. Mardis,et al.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay , 2015, BMC Medical Genomics.

[13]  A. Luini,et al.  Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.

[14]  Kathleen A Cronin,et al.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.

[15]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Rodenhuis,et al.  Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response , 2013, Breast Cancer Research and Treatment.

[17]  P. Neven,et al.  Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[19]  W. Sauerbrei,et al.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration , 2012, PLoS medicine.

[20]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[22]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[23]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.